RARE
Price
$39.29
Change
+$1.78 (+4.75%)
Updated
Jun 12 closing price
Capitalization
3.71B
48 days until earnings call
SNDX
Price
$10.67
Change
-$0.23 (-2.11%)
Updated
Jun 12 closing price
Capitalization
918.13M
59 days until earnings call
Interact to see
Advertisement

RARE vs SNDX

Header iconRARE vs SNDX Comparison
Open Charts RARE vs SNDXBanner chart's image
Ultragenyx Pharmaceutical
Price$39.29
Change+$1.78 (+4.75%)
Volume$1.92M
Capitalization3.71B
Syndax Pharmaceuticals
Price$10.67
Change-$0.23 (-2.11%)
Volume$1.53M
Capitalization918.13M
RARE vs SNDX Comparison Chart
Loading...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RARE vs. SNDX commentary
Jun 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RARE is a StrongBuy and SNDX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 13, 2025
Stock price -- (RARE: $37.51 vs. SNDX: $10.90)
Brand notoriety: RARE and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RARE: 142% vs. SNDX: 37%
Market capitalization -- RARE: $3.71B vs. SNDX: $918.13M
RARE [@Biotechnology] is valued at $3.71B. SNDX’s [@Biotechnology] market capitalization is $918.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $352B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RARE’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • RARE’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, SNDX is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RARE’s TA Score shows that 6 TA indicator(s) are bullish while SNDX’s TA Score has 5 bullish TA indicator(s).

  • RARE’s TA Score: 6 bullish, 2 bearish.
  • SNDX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RARE is a better buy in the short-term than SNDX.

Price Growth

RARE (@Biotechnology) experienced а +2.46% price change this week, while SNDX (@Biotechnology) price change was -0.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.07%. For the same industry, the average monthly price growth was +16.42%, and the average quarterly price growth was +7.21%.

Reported Earning Dates

RARE is expected to report earnings on Jul 31, 2025.

SNDX is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+6.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.72B) has a higher market cap than SNDX($918M). RARE YTD gains are higher at: -6.608 vs. SNDX (-19.289). SNDX has higher annual earnings (EBITDA): -318.27M vs. RARE (-449.9M). SNDX (516M) and RARE (494M) have equal amount of cash in the bank . SNDX has less debt than RARE: SNDX (1.84M) vs RARE (38.3M). RARE has higher revenues than SNDX: RARE (591M) vs SNDX (43.7M).
RARESNDXRARE / SNDX
Capitalization3.72B918M405%
EBITDA-449.9M-318.27M141%
Gain YTD-6.608-19.28934%
P/E RatioN/AN/A-
Revenue591M43.7M1,352%
Total Cash494M516M96%
Total Debt38.3M1.84M2,085%
FUNDAMENTALS RATINGS
RARE vs SNDX: Fundamental Ratings
RARE
SNDX
OUTLOOK RATING
1..100
1619
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
6063
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (79) in the Biotechnology industry is in the same range as SNDX (84). This means that RARE’s stock grew similarly to SNDX’s over the last 12 months.

RARE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SNDX (100). This means that RARE’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's SMR Rating (98) in the Biotechnology industry is in the same range as RARE (99). This means that SNDX’s stock grew similarly to RARE’s over the last 12 months.

RARE's Price Growth Rating (60) in the Biotechnology industry is in the same range as SNDX (63). This means that RARE’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for RARE (100). This means that SNDX’s stock grew significantly faster than RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RARESNDX
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 24 days ago
77%
Bullish Trend 16 days ago
83%
Declines
ODDS (%)
Bearish Trend 16 days ago
80%
Bearish Trend 29 days ago
77%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
APLY12.740.17
+1.35%
YieldMax AAPL Option Income Strategy ETF
RCG2.620.02
+0.89%
RENN Fund
BBRE94.150.30
+0.32%
JPMorgan BetaBuilders MSCI US REIT ETF
ONEQ77.410.14
+0.18%
Fidelity Nasdaq Composite ETF
HPF15.77-0.04
-0.23%
John Hancock Preferred Income Fund II

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with COGT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then COGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+4.75%
COGT - RARE
53%
Loosely correlated
-0.55%
CRNX - RARE
51%
Loosely correlated
-0.49%
DNLI - RARE
51%
Loosely correlated
-1.74%
RVMD - RARE
50%
Loosely correlated
+0.78%
ARWR - RARE
49%
Loosely correlated
-3.11%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with IDYA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
-2.11%
IDYA - SNDX
52%
Loosely correlated
+1.64%
ETNB - SNDX
51%
Loosely correlated
-4.18%
KRYS - SNDX
51%
Loosely correlated
+0.51%
CGON - SNDX
50%
Loosely correlated
+1.22%
RARE - SNDX
49%
Loosely correlated
+4.75%
More